MedTrace Logo

Analysis of Natural Killer Cell Activity (NKA) in Whole Blood in High Risk Subjects Undergoing Colonoscopy

NCT03249727 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 396

Last updated 2023-01-31

No results posted yet for this study

Summary

This study will measure the activity of natural killer (NK) cells using the in vitro diagnostic device NK Vue in high risk subjects (Quebec risk categories P2, P3 and P4) scheduled for colonoscopy.

Conditions

Interventions

DIAGNOSTIC_TEST

IVDD for NK cell activity in whole blood

Once subject has been scheduled for a colonoscopy by the institution (up to 4 weeks prior to procedure), the subject will perform a FIT at home and an NK Vue test (one sample of one mL of blood) at the institution, prior to the day of colonoscopy.

Sponsors & Collaborators

  • ATGen Canada Inc

    lead INDUSTRY

Principal Investigators

  • Gilles Jobin, MD, FRCP · CIUSSS de l'Est-de-l'île-de-Montréal; Installation Hôpital Maisonneuve-Rosemont

Study Design

Allocation
NA
Purpose
SCREENING
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-05
Primary Completion
2018-10-11
Completion
2018-10-11

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03249727 on ClinicalTrials.gov